Difficulty in predicting survival in metastatic renal cancer

Affiliations

Comment

Tom Powles et al. Lancet Oncol. 2012 Sep.

. 2012 Sep;13(9):859-60.

doi: 10.1016/S1470-2045(12)70318-2. Epub 2012 Aug 8.

¹ Experiment Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London EC1A 7BE, UK. thomas.powles@bartshealth.nhs.uk

No abstract available

Comment on

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Harshman LC, et al. Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877847 Free PMC article.